Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19

• URL: http://arxiv.org/abs/2004.07229v2
• Date: Sun, 9 Aug 2020 15:52:14 GMT
• Title: Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19
• Authors: Deisy Morselli Gysi and \'Italo Do Valle and Marinka Zitnik and Asher Ameli and Xiao Gan and Onur Varol and Susan Dina Ghiassian and JJ Patten and Robert Davey and Joseph Loscalzo and Albert-L\'aszl\'o Barab\'asi
• Abstract summary: The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. Here, we deploy algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics.
• Score: 6.7410870290301
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and disease genes. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs that had been experimentally screened in VeroE6 cells, and the list of drugs under clinical trial, that capture the medical community's assessment of drugs with potential COVID-19 efficacy. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics. This prompted us to develop a multimodal approach that fuses the predictions of all algorithms, showing that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We find that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these drugs rely on network-based actions that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.

Related papers

• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• Multiscale Topology in Interactomic Network: From Transcriptome to Antiaddiction Drug Repurposing [0.3683202928838613]
  The escalating drug addiction crisis in the United States underscores the urgent need for innovative therapeutic strategies. This study embarked on an innovative and rigorous strategy to unearth potential drug repurposing candidates for opioid and cocaine addiction treatment.
  arXiv  Detail & Related papers  (2023-12-03T04:01:38Z)
• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening [38.94493676651818]
  We propose a zero-shot learning solution for the. task in preclinical drug screening. Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA.
  arXiv  Detail & Related papers  (2023-10-05T05:55:41Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description [11.64859287146094]
  We propose KGML-xDTD: a Knowledge Graph-based Machine Learning framework for explainably predicting Drugs Treating Diseases. We leverage knowledge-and-publication based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning process.
  arXiv  Detail & Related papers  (2022-11-30T17:05:22Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data [56.53715632642495]
  Clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions.
  arXiv  Detail & Related papers  (2021-02-08T15:09:07Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.